The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. Sales ...

One of the key launch points for the modern biotechnology industry was not in the Bay Area or San Diego or Cambridge, ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 financial and operating results on ...

As the demand for GLP-1 weight loss medications such as Ozempic, Wegovy, and Zepbound continues to skyrocket, new survey ...

Restaurant Mama’s Kitchen is among awardees from across the country who received a special grant from Direct Relief’s Fund ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound ... which is based in both Boston and San Diego, emerged from ...

BOSTON and SAN DIEGO, Jan. 27, 2025 (GLOBE NEWSWIRE ... candidates for the treatment of obesity and related conditions. She joins Kailera from Eli Lilly where she held key roles in brand strategy, ...

AdLB has received consulting fees from AGTC, Alchemab, Alector, Alzprotect, Amylyx, Arkuda, Arrowhead, Arvinas, Aviado, Eli Lilly ... agreements with US San Diego for consulting activities ...